COYA

2.9501.01%
DA

Dov A. Goldstein

Independent Director

Dr. Dov A. Goldstein, M.D., M.B.A, has been an Independent Director at Coya Therapeutics, Inc. since March 2021. He is the Chief Financial Officer at BioAge Labs, Inc. since November 2021. He was Chief Financial Officer and Chief Business Officer of Indapta Therapeutics from 2020 to 2021. Dr. Goldstein previously served as Chief Executive Officer at RIGImmune from 2018 to 2020. Dr. Goldstein was the Chief Financial Officer at Schrodinger, Inc. from 2017 to 2018. Prior to joining Vicuron, he was Director of Venture Analysis at HealthCare Ventures LLC. He served as a Managing Partner at Aisling Capital Management LP from 2014 to 2017, where he sourced and led investments in private and public companies. He joined Aisling Capital Management LP in 2006. He previously served as its Operating Partner. Dr. Goldstein served as the Acting Chief Financial Officer at Loxo Oncology, Inc. since January 2015 until May 1, 2015. He is an Independent Director of NeuBase Therapeutics, Inc. from July 12, 2019 and serves as its Chairperson since October 14, 2022. He served as the Chief Financial Officer at Loxo Oncology, Inc. since July 2014 until January 2015. Dr. Goldstein served as the Chief Financial Officer at Vicuron Pharmaceuticals, Inc. since July 2000 until 2005 which was acquired by Pfizer, Inc. in September 2005 and served as its Executive Vice President since August 2003 until 2005. He also served as Executive Vice President of Finance and Vice President of Finance at Vicuron Pharmaceuticals, Inc. from July 2000 to August 2003 and also served as its Secretary. Dr. Goldstein led the valuation and finance due diligence for the merger with Biosearch Italia. He also ran the Investor Relations and press relations efforts for the company. Dr. Goldstein served as a Director of Venture Analysis at HealthCare Ventures. He served as a Vice President of biotechnology research analysis at Brean Murray & Co. from 1997 to 1998. Dr. Goldstein completed his internship in the Department of Medicine at Columbia-Presbyterian Hospital. He has in strategic financial and operational experience in the healthcare sector. He had been a Director at ADMA Biologics, Inc. since 2007 until June 18, 2020. Dr. Goldstein has been a Director of Cempra, Inc. since January 2008. Dr. Goldstein was the Chief Financial Officer at Schrodinger, LLC from 2017 to 2018. He has experience in medical training and in the biopharmaceutical industry as a venture capital Investor. He served as a Director at Vicuron Pharmaceuticals, Inc. and has been Director of CardioKine, Inc. and Scerene Healthcare, Inc. He is a Director of Gain Therapeutics, Inc. since January 2021. Dr. Goldstein serves as a Board Observer and served as Director of Cempra Pharmaceuticals, Inc. He was a Director of Esperion Therapeutics, Inc. since April 2008 until May 29, 2019. He served as a Director at Topaz Pharmaceuticals, Inc. (now Sanofi-Topaz Inc.) since December 2007. Dr. Goldstein served as a Director of Loxo Oncology, Inc. from July 2013 to October 2014; BioRelix, Inc. since June 2007 and Durata Therapeutics, Inc. from December 2009 to May 16, 2013. He served on the Board of Duranta Therapeutics. He has many years of strategic financial and operational experience within the healthcare sector. Dr. Goldstein holds an M.D. from Yale University School of Medicine, an M.B.A. from Columbia Business School and a B.S., with honors, in Biological Sciences and Biology from Stanford University.

Positions